ATE396710T1 - Gastroretentive zusammensetzungen und verfahren zur herstellung - Google Patents

Gastroretentive zusammensetzungen und verfahren zur herstellung

Info

Publication number
ATE396710T1
ATE396710T1 AT05291542T AT05291542T ATE396710T1 AT E396710 T1 ATE396710 T1 AT E396710T1 AT 05291542 T AT05291542 T AT 05291542T AT 05291542 T AT05291542 T AT 05291542T AT E396710 T1 ATE396710 T1 AT E396710T1
Authority
AT
Austria
Prior art keywords
producing
gastroretentive compositions
gastroretentive
formulations
gelling agent
Prior art date
Application number
AT05291542T
Other languages
English (en)
Inventor
Mahendra Chaudhari
Omprakash D Chandwan Chandwani
Rajashree Bhalchan Yelegaonkar
Original Assignee
Ethypharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Sa filed Critical Ethypharm Sa
Application granted granted Critical
Publication of ATE396710T1 publication Critical patent/ATE396710T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
AT05291542T 2005-07-19 2005-07-19 Gastroretentive zusammensetzungen und verfahren zur herstellung ATE396710T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05291542A EP1745775B1 (de) 2005-07-19 2005-07-19 Gastroretentive Zusammensetzungen und Verfahren zur Herstellung

Publications (1)

Publication Number Publication Date
ATE396710T1 true ATE396710T1 (de) 2008-06-15

Family

ID=35517256

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05291542T ATE396710T1 (de) 2005-07-19 2005-07-19 Gastroretentive zusammensetzungen und verfahren zur herstellung

Country Status (13)

Country Link
US (1) US9629800B2 (de)
EP (2) EP1745775B1 (de)
JP (1) JP5199084B2 (de)
KR (1) KR101367814B1 (de)
CN (1) CN101237858B (de)
AT (1) ATE396710T1 (de)
AU (1) AU2006271314B2 (de)
BR (1) BRPI0612901B8 (de)
CA (1) CA2616081C (de)
DE (1) DE602005007205D1 (de)
HK (1) HK1122729A1 (de)
RU (1) RU2376983C2 (de)
WO (1) WO2007010400A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
WO2010038237A2 (en) 2008-09-22 2010-04-08 Rubicon Research Private Limited Compositions exhibiting delayed transit through the gastrointestinal tract
FR2945947B1 (fr) 2009-05-29 2011-07-29 Flamel Tech Sa Compositions pharmaceutiques flottantes a liberation controlee
WO2011004799A1 (ja) 2009-07-06 2011-01-13 杏林製薬株式会社 中空構造を有する錠剤
EP2361615A1 (de) 2010-02-19 2011-08-31 Alfred E. Tiefenbacher GmbH & Co. KG Tablette mit verlängerter Dipyridamolfreisetzung
EP2544666A2 (de) 2010-03-09 2013-01-16 Council of Scientific and Industrial Research Gastroretentive retard-zusammensetzung eines therapeutikums
ES2543108T3 (es) * 2010-03-31 2015-08-14 Mochida Pharmaceutical Co., Ltd. Preparación sólida fácilmente administrable
CN101919817B (zh) * 2010-07-23 2012-05-30 山东齐都药业有限公司 一种拉呋替丁胃内滞留控制释放组合物
CA2847614C (en) 2011-09-30 2018-10-23 Mochida Pharmaceutical Co., Ltd. Easily dosable solid preparation
DE102012102414A1 (de) 2012-03-21 2013-10-10 Michael Dittgen Pharmazeutische Zusammensetzung für die einmal tägliche Anwendung antidiabetischer Arzneimittel wie Metformin mit Zwei-Puls-Freisetzung
WO2013168179A2 (en) * 2012-04-03 2013-11-14 Rubicon Research Private Limited Controlled release pharmaceutical formulations of antiviral agents
CN103110601B (zh) * 2013-02-04 2014-10-29 成都恒瑞制药有限公司 一种格列齐特胃漂浮片及其制备方法
FR3014692B1 (fr) * 2013-12-18 2016-01-29 Ethypharm Sa Compositions pharmaceutiques orales a retention gastrique.
TWI732337B (zh) * 2014-06-20 2021-07-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
CN109310653A (zh) 2016-03-17 2019-02-05 硫创治疗公司 用于控制释放半胱胺和系统治疗半胱胺敏感性病症的组合物
CN107184560B (zh) * 2017-06-03 2021-02-02 寿光富康制药有限公司 二甲双胍胃滞留片及制备方法
CA3076392A1 (en) 2017-09-20 2019-03-28 Thiogenesis Therapeutics, Inc. Methods for the treatment of cysteamine sensitive disorders
WO2019126215A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US11337919B2 (en) * 2017-12-18 2022-05-24 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
CN109602714B (zh) * 2018-12-29 2020-06-12 广东中润药物研发有限公司 一种利伐沙班胃滞留片及其制备方法
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
US20240065976A1 (en) * 2021-01-13 2024-02-29 DuPont Nutrition USA, Inc. A gastroretentive drug delivery system

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61148115A (ja) * 1984-12-21 1986-07-05 Tooa Eiyoo Kk 難溶性薬物の徐放性製剤及びその製造法
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
FR2653337B1 (fr) * 1989-10-23 1992-02-07 Dow Corning Sa Element a liberation prolongee et procede pour le fabriquer.
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
AU8699298A (en) * 1997-08-11 1999-03-01 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
AP1224A (en) 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
OA11652A (en) * 1998-09-14 2004-12-08 Ranbaxy Lab Ltd Orally administered controlled drug delivery system providing temporal and spatial control.
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
DE69927708T2 (de) * 1998-12-23 2006-07-06 Alza Corp., Mountain View Dosierungsformen, die poröse partikel enthalten
US6635281B2 (en) * 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
CA2400950A1 (en) * 2000-03-03 2001-09-07 Ranbaxy Laboratories Limited Orally administered controlled delivery system for once daily administration of ciprofloxacin
US20060099245A1 (en) * 2000-08-01 2006-05-11 Manoj Kumar Hydrodynamically balancing oral drug delivery system with biphasic release
CN1520286B (zh) * 2001-07-04 2010-12-01 太阳医药工业有限公司 胃滞留控制药物释出系统
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US7157100B2 (en) 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
WO2005060942A1 (en) * 2003-12-19 2005-07-07 Aurobindo Pharma Ltd Extended release pharmaceutical composition of metformin

Also Published As

Publication number Publication date
US9629800B2 (en) 2017-04-25
KR101367814B1 (ko) 2014-02-27
AU2006271314A1 (en) 2007-01-25
BRPI0612901B8 (pt) 2021-05-25
BRPI0612901B1 (pt) 2020-08-04
RU2376983C2 (ru) 2009-12-27
AU2006271314B2 (en) 2011-07-07
CA2616081A1 (en) 2007-01-25
EP1904034A2 (de) 2008-04-02
WO2007010400A3 (en) 2007-04-05
DE602005007205D1 (de) 2008-07-10
RU2008106220A (ru) 2009-08-27
HK1122729A1 (en) 2009-05-29
WO2007010400A2 (en) 2007-01-25
CA2616081C (en) 2013-09-10
US20080220060A1 (en) 2008-09-11
KR20080048461A (ko) 2008-06-02
CN101237858A (zh) 2008-08-06
EP1745775B1 (de) 2008-05-28
BRPI0612901A2 (pt) 2010-12-07
JP2009501777A (ja) 2009-01-22
EP1745775A1 (de) 2007-01-24
CN101237858B (zh) 2012-07-04
JP5199084B2 (ja) 2013-05-15

Similar Documents

Publication Publication Date Title
ATE396710T1 (de) Gastroretentive zusammensetzungen und verfahren zur herstellung
NO2020010I1 (no) fostamatinib eller et farmasøytisk akseptabelt salt av fostamatinib, eller et hydrat, solvat eller N-oksid av fostamatinib eller det farmasøytisk akseptable saltet av fostamatinib, spesielt fostamatinib dinatrium, eventuelt på form av et hydrat
ATE520427T1 (de) Poröse intravaskuläre embolisierungsteilchen und verfahren zu deren herstellung
DK1896006T3 (da) Fremstillingmetode for entacapon-holdige granuler til orale doseringsformet
CY1115199T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση
ATE426575T1 (de) Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
BRPI0508064A (pt) flavivìrus, composição de vacina e molécula de ácido nucléico
ATE458535T1 (de) Verfahren zur herstellung von konzentrierten tensidzusammensetzungen
BRPI0516735B8 (pt) métodos para produção de (r)-2-acetamido-n-benzil-3-metoxipropionamida (lacosamida) e de uma formulação farmacêutica, e uso de (r)-n-benzil-2-nboc-amino-3-metoxipropionamida (c-937)
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
MX2007008636A (es) Biopolimero que incluye prolamina y metodos para elaborarlo.
ECSP099529A (es) Inhibidores de cinasa mapk/erk
UA92894C2 (ru) Способ приготовления и применения композиции адсорбента фосфата, адсорбент фосфата, композиция адсорбента фосфата
ATE501264T1 (de) Enzymatische verfahren zur herstellung 4- substituierter 3-hydroxybuttersäure-derivate
IL193024A0 (en) Levetiracetam formulations and methods for their manufacture
WO2007025146A3 (en) Balsalazide formulations and manufacture and use thereof
DE602004026522D1 (de) Target für Elektronstrahlverdampfung und Verfahren zur dessen Herstellung.
HRP20070487T3 (en) Preparing aldesleukin for pharmaceutical use
TW200716167A (en) Formulations and process for production of bordetella bronchiseptica P68 antigen and vaccines
WO2006105441A3 (en) Fiber constructs comprising bioactive materials and process of fiber fabrication
HN2001000225A (es) Composicion blanqueante dental y procedimiento que emplea un agente blanqueante acido dicarboxilico
CR9472A (es) Derivados de aminoacidos
DE602006000353D1 (de) Anschlusssteckverbinder, Materialzuschnitt und Verfahren zur Herstellung
ATE500726T1 (de) Tierstreu und herstellungsverfahren dafür
WO2007002881A3 (en) Compositions and methods of use of derivatized flavanols

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties